Psyence Group Inc. (TSE:PSYG) has released an update.
Psyence Group Inc’s associate, Psyence Biomedical, has received approval to begin a Phase IIb clinical trial in Melbourne, Australia, to explore the effects of nature-derived psilocybin on Adjustment Disorder in palliative care patients. The study will test various doses alongside psychotherapy, aiming to improve the quality of life for those with life-limiting illnesses. This research could represent a shift in palliative care treatment, addressing a significant unmet medical need.
For further insights into TSE:PSYG stock, check out TipRanks’ Stock Analysis page.
